Suppr超能文献

停用泼尼松后环孢素治疗的小儿肾移植受者的随访

Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone.

作者信息

Reisman L, Lieberman K V, Burrows L, Schanzer H

机构信息

Jack and Lucy Clark Department of Pediatrics, Mount Sinai School of Medicine, New York, New York 10029.

出版信息

Transplantation. 1990 Jan;49(1):76-80. doi: 10.1097/00007890-199001000-00017.

Abstract

We attempted cessation of prednisone therapy in 16 pediatric renal allograft recipients who were between the ages of 3 1/2 and 16 years at the time of transplantation. Fourteen had primary grafts and 2 had second grafts. Nine had cadaver and 7 had living-related donor grafts. At the time of cessation of prednisone, cyclosporine was the only other immunosuppressive therapy for 15 of the patients and 1 patient was receiving CsA and azathioprine. All the patients had stable serum creatinines at the time prednisone was stopped, between 7 months and 5 years posttransplantation. Seven patients have had no episodes of rejection, continuing to receive CsA as their only immunosuppressive therapy and have stable renal function between 16 months and 3 1/2 years (mean: 2 years) after stopping prednisone. Stopping the small maintenance dose of prednisone resulted in improved growth in patients whose epiphyses were not fused. They improved their weight:height ratios and lost their cushingoid appearance. Serum cholesterol levels declined significantly. Patients who required antihypertensive drugs to control their blood pressure while receiving prednisone required fewer or no drugs when off prednisone. Nine patients had acute rejection episodes and were put back on maintenance prednisone following a 3-day steroid pulse. All these patients had a prompt improvement in renal function following the steroid pulse. However, only 3 stabilized function at preprotocol baseline Scr. Four currently have functioning grafts with Scr greater than the preprotocol Scr. Two patients have returned to dialysis. Although stopping steroids is a worthy goal in pediatric renal allograft recipients, we cannot recommend this strategy as routine management because of the 56% rate of acute rejection episodes in the patients who had prednisone withdrawn.

摘要

我们尝试对16例小儿肾移植受者停用泼尼松治疗,这些受者在移植时年龄为3.5岁至16岁。14例接受的是初次移植,2例接受的是再次移植。9例接受的是尸体供肾移植,7例接受的是亲属活体供肾移植。在停用泼尼松时,15例患者仅接受环孢素作为其他免疫抑制治疗,1例患者同时接受环孢素和硫唑嘌呤治疗。所有患者在停用泼尼松时血清肌酐均稳定,移植后7个月至5年。7例患者未发生排斥反应,继续仅接受环孢素作为免疫抑制治疗,在停用泼尼松后16个月至3.5年(平均2年)肾功能稳定。停用小剂量维持量泼尼松后,骨骺未融合的患者生长情况改善。他们的体重身高比得到改善,库欣样外观消失。血清胆固醇水平显著下降。在接受泼尼松治疗时需要使用抗高血压药物控制血压的患者,停用泼尼松后所需药物减少或不再需要用药。9例患者发生急性排斥反应,在进行3天的类固醇冲击治疗后重新开始维持量泼尼松治疗。所有这些患者在类固醇冲击治疗后肾功能迅速改善。然而,只有3例患者的肾功能在方案前基线血清肌酐水平稳定。目前有4例患者的移植肾仍在发挥功能,但血清肌酐高于方案前水平。2例患者已重新开始透析。虽然停用类固醇是小儿肾移植受者的一个值得追求的目标,但由于停用泼尼松的患者中有56%发生急性排斥反应,我们不建议将此策略作为常规治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验